Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 17 January 2003:
Vol. 299. no. 5605, pp. 350 - 351
DOI: 10.1126/science.1077141
Prev | Table of Contents | Next

Policy Forum

MEDICINE:
What Are the Right Targets for Psychopharmacology?

Steven E. Hyman and Wayne S. Fenton

Successive generations of medicines to treat mental illness have reduced the burden of suffering for these diseases, but for many patients, treatment-resistant symptoms and disabilities suggest we must do better. It is widely recognized that advances in genetics and molecular neurobiology will hasten the identification of new molecular targets, but these may not result in effective new treatments unless we also develop better "clinical targets": dimensions of psychopathology or dysfunction more proximate to pathophysiology. Such clinical targets are not necessarily well represented in our currently accepted clinical endpoints and consensus-derived diagnostic systems for mental disorders.

S. E. Hyman is at Harvard University, Boston, MA 02138, USA. W. S. Fenton is at the National Institute of Mental Health, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20896, USA.

*To whom correspondence should be addressed. E-mail: wfenton{at}mail.nih.gov and SEH{at}harvard.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Targeting Cognition in Schizophrenia Research: From Etiology to Treatment.
T. E. Goldberg and J. J. Gomar (2009)
Am J Psychiatry 166, 631-634
   Full Text »    PDF »
Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST).
M. Davidson, S. Galderisi, M. Weiser, N. Werbeloff, W. W. Fleischhacker, R. S. Keefe, H. Boter, I. P.M. Keet, D. Prelipceanu, J. K. Rybakowski, et al. (2009)
Am J Psychiatry 166, 675-682
   Abstract »    Full Text »    PDF »
Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia.
D. A. Lewis, R. Y. Cho, C. S. Carter, K. Eklund, S. Forster, M. A. Kelly, and D. Montrose (2008)
Am J Psychiatry 165, 1585-1593
   Abstract »    Full Text »    PDF »
Accelerating New Knowledge in Schizophrenia.
C. A. Tamminga (2008)
Am J Psychiatry 165, 949-951
   Full Text »    PDF »
Comparing Genes and Phenomenology in the Major Psychoses: Schizophrenia and Bipolar 1 Disorder.
E. Ivleva, G. Thaker, and C. A. Tamminga (2008)
Schizophr Bull 34, 734-742
   Full Text »    PDF »
Neurocognition as a Treatment Target in Schizophrenia.
S. R. Marder (2008)
Focus 6, 180-183
   Abstract »    Full Text »    PDF »
Bibliography Schizophrenia.
(2008)
Focus 6, 197-199
   Full Text »    PDF »
Schizophrenia: Moving Beyond Monoamine Antagonists.
P. J. Conn, C. Tamminga, D. D. Schoepp, and C. Lindsley (2008)
Mol. Interv. 8, 99-107
   Abstract »    Full Text »    PDF »
Wayne Fenton, M.D..
E. Stover, and T. R. Insel (2008)
Am J Psychiatry 165, 177-178
   Full Text »    PDF »
Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function.
W. S. Stone and L. J. Seidman (2008)
Schizophr Bull 34, 93-108
   Abstract »    Full Text »    PDF »
A Review of the Effects of Modafinil on Cognition in Schizophrenia.
S. Morein-Zamir, D. C. Turner, and B. J. Sahakian (2007)
Schizophr Bull 33, 1298-1306
   Abstract »    Full Text »    PDF »
Wayne Fenton's Impact on Academic Neuroscience.
M. A. Geyer and C. A. Tamminga (2007)
Schizophr Bull 33, 1156-1159
   Abstract »    Full Text »    PDF »
New Paradigms for Treatment Development.
E. L. Stover, L. Brady, and S. R. Marder (2007)
Schizophr Bull 33, 1093-1099
   Abstract »    Full Text »    PDF »
Cognition, Drug Treatment, and Functional Outcome in Schizophrenia: A Tale of Two Transitions.
M. F. Green (2007)
Am J Psychiatry 164, 992-994
   Full Text »    PDF »
The Neuropharmacology of Psychosis.
C. A. Tamminga and J. M. Davis (2007)
Schizophr Bull 33, 937-946
   Abstract »    Full Text »    PDF »
How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment?.
R. S. E. Keefe and W. S. Fenton (2007)
Schizophr Bull 33, 912-920
   Abstract »    Full Text »    PDF »
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial.
R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al. (2007)
Arch Gen Psychiatry 64, 633-647
   Abstract »    Full Text »    PDF »
Commentary on "A Neurosciences-in-Psychiatry Curriculum Project for Medical Students".
F. S. Sierles (2006)
Acad Psychiatry 30, 101-102
   Full Text »    PDF »
A Neurosciences-in-Psychiatry Curriculum Project for Medical Students.
D. C. Dunstone (2006)
Acad Psychiatry 30, 166-169
   Abstract »    Full Text »    PDF »
The neural basis of relational memory deficits in schizophrenia..
D. Ongur, T. J. Cullen, D. H. Wolf, M. Rohan, P. Barreira, M. Zalesak, and S. Heckers (2006)
Arch Gen Psychiatry 63, 356-365
   Abstract »    Full Text »    PDF »
Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms.
C. R. Bowie, A. Reichenberg, T. L. Patterson, R. K. Heaton, and P. D. Harvey (2006)
Am J Psychiatry 163, 418-425
   Abstract »    Full Text »    PDF »
Psychopharmacology and memory.
W Glannon (2006)
J. Med. Ethics 32, 74-78
   Abstract »    Full Text »    PDF »
A Collaborative Approach to Targeted Treatment Development for Schizophrenia: A Qualitative Evaluation of the NIMH-MATRICS Project.
E. Bromley (2005)
Schizophr Bull 31, 954-961
   Abstract »    Full Text »    PDF »
New Approaches to Measurement and Treatment Research to Improve Cognition in Schizophrenia.
M. A Geyer and R. Heinssen (2005)
Schizophr Bull 31, 806-809
   Abstract »    Full Text »    PDF »
Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia.
J. J Hagan and D. N C Jones (2005)
Schizophr Bull 31, 830-853
   Abstract »    Full Text »    PDF »
Regulation of synaptic plasticity in a schizophrenia model.
B. Gisabella, V. Y. Bolshakov, and F. M. Benes (2005)
PNAS 102, 13301-13306
   Abstract »    Full Text »    PDF »
Differential Modulation of Glutamatergic Transmission by 3,5-Dibromo-L-phenylalanine.
V. Yarotskyy, A. V. Glushakov, C. Sumners, N. Gravenstein, D. M. Dennis, C. N. Seubert, and A. E. Martynyuk (2005)
Mol. Pharmacol. 67, 1648-1654
   Abstract »    Full Text »    PDF »
Familiality of Symptom Dimensions in Depression.
A. Korszun, V. Moskvina, S. Brewster, N. Craddock, F. Ferrero, M. Gill, I. R. Jones, L. A. Jones, W. Maier, O. Mors, et al. (2004)
Arch Gen Psychiatry 61, 468-474
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)